Evidence map›Paper›PMID 42429844›Full record

ReviewMolecular biology reports2026

Redefining Neutrophil Function in Inflammatory Bowel Disease: From Tissue Injury to Immune Resolution.

Melika Khademi, Nesa Kazemifard, Shaghayegh Baradaran Ghavami, Maryam Farmani, Shabnam Shahrokh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Melika KhademiGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Nesa KazemifardGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shaghayegh Baradaran GhavamiGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Shaghayegh.bghavami@gmail.com.ORCID https://orcid.org/0000-0003-0359-8653
Maryam FarmaniGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shabnam ShahrokhGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation driven by dysregulated immune responses and impaired mucosal homeostasis. Although neutrophils have traditionally been viewed as short-lived pro-inflammatory effector cells that contribute to epithelial injury, emerging evidence indicates that they also possess important pro-resolving and tissue-repairing functions. This narrative mini-review critically evaluates recent advances in understanding neutrophil functional heterogeneity in IBD, with particular emphasis on CD177⁺ neutrophils, neutrophil extracellular trap formation, efferocytosis, and mechanisms involved in immune resolution and mucosal healing. Accumulating data suggest that specialized neutrophil subsets can balance antimicrobial defense with controlled inflammatory signaling, thereby contributing to epithelial protection and restoration of intestinal homeostasis. In parallel, efficient efferocytosis of apoptotic neutrophils by macrophages emerges as a central mechanism promoting resolution of inflammation, whereas impaired clearance sustains chronic inflammatory responses. Recent studies further highlight the therapeutic potential of targeting pro-resolving neutrophil pathways and enhancing efferocytosis; however, most current evidence remains preclinical, and significant challenges persist in translating these findings into human therapies. Collectively, these insights redefine neutrophils as dynamic regulators of both tissue injury and immune resolution in IBD and support the development of therapeutic strategies aimed at restoring immune balance and durable mucosal healing.

Indexed as

Inflammatory Bowel DiseasesNeutrophilsAnimalsApoptosisEfferocytosisExtracellular TrapsGPI-Linked ProteinsHumansInflammationIntestinal MucosaIsoantigensMacrophagesReceptors, Cell SurfaceCD177 protein, humanGPI-Linked ProteinsIsoantigensReceptors, Cell SurfaceCD177⁺ neutrophilsEfferocytosisImmune resolutionInflammatory bowel diseaseMucosal healingNeutrophils

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.